Teladoc Health Target of Unusually High Options Trading (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC) was the target of some unusual options trading activity on Thursday. Investors acquired 15,650 call options on the company. This represents an increase of 30% compared to the average daily volume of 12,026 call options.

Teladoc Health News Roundup

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter adjusted loss of $0.21 per share, better than the consensus estimate of a $0.24 loss. Strength in Integrated Care and international operations helped offset weakness in BetterHelp. Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
• Positive Sentiment: Management’s cost controls and efficiency measures appear to be narrowing losses over the first half of 2026, while some investors see the stock as potentially undervalued following the selloff. Teladoc Health Could Be Undervalued
• Neutral Sentiment: Canaccord Genuity maintained a Buy rating but lowered its price target from $11 to $10. Separately, traders purchased about 15,650 call options, roughly 30% above typical volume, suggesting some speculative bullish positioning but not necessarily a change in fundamentals.
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, missing analysts’ $615.4 million estimate. Teladoc also posted a $38.9 million net loss, or $0.21 per share, compared with a $0.19 loss in the year-earlier quarter. Teladoc Tumbles on Revenue Forecast Cut
• Negative Sentiment: The key pressure is BetterHelp, where shifting demand reduced cash-pay revenue. After a 12% annual decline in the latest quarter, the company indicated the division could decline as much as 19% for the full year, undermining expectations for a recovery. Teladoc Health Investigation Notice
• Negative Sentiment: Teladoc’s third-quarter revenue outlook of approximately $589 million was below expectations, and the company lowered its full-year revenue forecast. The weaker outlook outweighed the adjusted earnings beat and caused analysts and investors to reset expectations for growth and profitability. Teladoc Stock Plummets on Revenue Miss and Lowered Outlook
• Negative Sentiment: Levi & Korsinsky announced a pending investigation into Teladoc, adding potential legal and reputational risk to an already weak earnings narrative. The investigation notice does not establish wrongdoing, but it may further weigh on sentiment.

Insider Activity at Teladoc Health

In related news, insider Adam C. Vandervoort sold 7,906 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $60,322.78. Following the completion of the transaction, the insider owned 110,261 shares of the company’s stock, valued at approximately $841,291.43. This trade represents a 6.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of Teladoc Health stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $145,977.16. Following the completion of the sale, the chief executive officer owned 389,894 shares of the company’s stock, valued at $2,974,891.22. This trade represents a 4.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 39,195 shares of company stock valued at $299,058 in the last ninety days. Insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

Several large investors have recently bought and sold shares of TDOC. Jupiter Asset Management Ltd. raised its position in Teladoc Health by 293.9% in the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock valued at $27,021,000 after purchasing an additional 2,880,008 shares in the last quarter. Quantinno Capital Management LP grew its position in shares of Teladoc Health by 128.0% during the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock worth $14,287,000 after buying an additional 1,471,631 shares in the last quarter. Pale Fire Capital SE grew its position in shares of Teladoc Health by 74.8% during the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock worth $18,522,000 after buying an additional 1,454,288 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Teladoc Health by 23.8% during the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock worth $53,260,000 after buying an additional 1,325,106 shares during the period. Finally, Trexquant Investment LP purchased a new stake in shares of Teladoc Health during the fourth quarter worth approximately $9,156,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on TDOC. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Citigroup boosted their price objective on Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a report on Tuesday, May 5th. Bank of America increased their target price on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Finally, Canaccord Genuity Group lowered their target price on Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Teladoc Health currently has an average rating of “Hold” and a consensus price target of $7.50.

Teladoc Health Price Performance

Teladoc Health stock opened at $6.71 on Friday. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. Teladoc Health has a 52-week low of $4.40 and a 52-week high of $9.89. The firm has a market cap of $1.21 billion, a PE ratio of -6.78 and a beta of 2.10. The company’s 50 day moving average is $8.21 and its two-hundred day moving average is $6.54.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.02%. The business had revenue of $606.93 million during the quarter, compared to the consensus estimate of $615.44 million. During the same quarter in the previous year, the firm posted ($0.19) earnings per share. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, research analysts expect that Teladoc Health will post -0.89 EPS for the current fiscal year.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.